Redefining the speed and safety of drug discovery and biobetter engineering through zero-hallucination AI and formal verification.
Polyphoros is an AI-Native Biotechnology company redefining the speed, safety, and deterministic nature of drug discovery.
While the industry relies on probabilistic models that discover efficacy "by chance," we integrate formal logic (Lean 4 theorem proving), multi-agent orchestration, and large-scale knowledge graphs. Polyphoros eliminates the critical bottleneck of AI hallucinations in computational pharmacology.
We don't just predict molecules; we mathematically verify their safety pathways before in vivo trials.
Why Polyphoros structurally outperforms billion-dollar incumbents like Insilico Medicine and Recursion Pharmaceuticals.
Legacy AI-biotech relies on statistical LLMs and unverified generative models. Biology remains a "black box", inevitably leading to AI-hallucinations, off-target toxicity, and multi-billion-dollar clinical failures.
We translate biology into strict mathematics. Every molecule generated is formally verified and mathematically proven safe by the Lean 4 compiler before it ever touches a test tube.
Competitors burn hundreds of millions of dollars building massive physical robotic factories to screen thousands of generated compounds, hoping a few survive in vitro testing.
We hit with logic accuracy, not brute-force volume. By proving ADMET safety pathways virtually, we bypass the need for mega-factories, executing a highly capital-efficient, IP-centric business model.
A proprietary, deterministic 4-stage in silico pipeline for targeted drug design.
Utilizing dynamic cellular pathway grounding and large-scale knowledge graphs to identify exactly disrupted Gene Regulatory Networks (GRN).
Multi-agent routing to synthesize novel chemical entities (NCEs) or radically optimize existing scaffolds for maximum bioavailability.
The industry's first mathematical safety filter. We use formal theorem proving (Lean 4) to guarantee ADMET compliance prior to synthesis.
Addressing unmet medical needs with regionally optimized, high-margin Biobetters designed for rapid out-licensing.
| Program (Small Molecule) | Target | Indication | Stage |
|---|---|---|---|
| 📍 RUSSIA & CIS REGION (Sanction-Resistant Biobetters) | |||
| Modified Niclosamide Scaffold: Niclosamide + Fluorinated Radical | STAT3 | Colorectal Cancer (CRC) / IBD | In Silico Optimization |
| Oral Next-Gen Inhibitor Scaffold: Lapatinib + Michael Acceptor | HER2 Kinase Domain | Targeted Oncology | Target Identification |
| Selective Inhibitor Scaffold: Crizotinib + Aromatic Radical | METex14 | Non-Small Cell Lung Cancer | Target Identification |
| 📍 UAE / MENA REGION (Metabolic & Rare Diseases) | |||
| Next-Gen Oral GLP-1R Agonist Scaffold: Loxoprofen + Azabicyclic core | GLP-1 Receptor | Severe Obesity / Type 2 Diabetes | In Silico Optimization |
| Covalent JAK1/TNF-α Suppressor Scaffold: Trapidil + Michael Acceptor | JAK1 / TNF-α | Autoimmune (IBD, Rheumatoid Arthritis) | Target Identification |
| Lysosomal Chaperone (Poly-003) Scaffold: Deuterated Ambroxol | Mutant GBA Enzyme | Gaucher Disease (Consanguinity focus) | Target Identification |
| FNIP1 PROTAC Degrader First-in-Class Metabolic Switch | FNIP1 / Folliculin Axis | Metabolic Syndrome (Muscle-sparing) | Exploratory R&D |
| 📍 EUROPE: DACH REGION (Immunology & Neurodegeneration) | |||
| Next-Gen Oral TYK2 Inhibitor Scaffold: Deucravacitinib Optimization | TYK2 Pseudokinase | Resistant Crohn’s Disease / IBD | Target Identification |
| Oral Trem2 / ApoE Modulator Scaffold: Minnelide Derivatives | Trem2-Stabilizing Cleavage | Early-Stage Alzheimer’s | Exploratory R&D |
| 📍 CHINA / APAC REGION (Targeted Oncology) | |||
| Oral Pan-RAF Inhibitor Scaffold: Sorafenib + Conformation Lock | BRAF/CRAF Complexes | Hepatocellular Carcinoma (HCC) | In Silico Optimization |
| Dual CLDN18.2 / EGFR Inhibitor Scaffold: Quinazoline Derivatives | Claudin 18.2 & EGFR | Gastric Adenocarcinoma | In Silico Optimization |
Beyond our internal therapeutic assets, Polyphoros offers exclusive co-development agreements to Big Pharma and research institutions. We deploy the Q.E.D. Engine to solve your specific clinical bottlenecks—whether it's overcoming target resistance, reducing off-target toxicity, or executing rapid computational drug repurposing.
Request Collaboration